Nikhil Prasad Fact checked by:Thailand Medical News Team Feb 24, 2025 3 hours, 20 minutes ago
Medical News: A recent study conducted by researchers from "Victor Babes" University of Medicine and Pharmacy in Timisoara, Romania, has made significant progress in identifying biomarkers associated with inflammation and tissue damage in patients suffering from long-term effects of COVID-19. The research provides a clearer understanding of how the virus impacts multiple organs even after recovery from the acute phase of infection. This
Medical News report delves into the findings and their implications for the future of COVID-19 treatment and patient care.
Key Biomarkers of Inflammation and Tissue Damage in COVID-19 Patients
The Role of Biomarkers in Post-COVID-19 Conditions
The study highlights both well-established and newly emerging biomarkers that can help monitor ongoing inflammation and organ damage in COVID-19 survivors. Among the key markers identified are C-reactive protein (CRP) and interleukin-6 (IL-6), which indicate persistent inflammation. The researchers also explored newer biomarkers such as soluble urokinase plasminogen activator receptor (suPAR) and neutrophil extracellular traps (NETs), both of which offer critical insights into prolonged immune system activation and tissue damage.
CRP, a widely recognized marker of inflammation, was found to remain elevated in many patients experiencing post-COVID-19 symptoms. High levels of IL-6, a cytokine involved in immune response regulation, were also linked to ongoing inflammation in recovered patients. The study suggests that these markers could be useful in identifying individuals at risk for long-term complications and guiding treatment strategies to manage post-COVID-19 conditions effectively.
Organ-Specific Damage and Long-Term Impacts
The research also examined how COVID-19 affects different organ systems over the long term. For instance, persistent lung damage was linked to elevated levels of Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), two biomarkers associated with pulmonary fibrosis and reduced lung function. Patients with ongoing respiratory symptoms were found to have significantly higher levels of these markers, indicating long-term lung damage and scarring.
In addition to respiratory complications, neurological symptoms such as brain fog, memory impairment, and headaches were common in long COVID patients. Researchers identified elevated levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as indicators of ongoing neuroinflammation and neuronal damage. These findings suggest that the virus may have long-lasting effects on the brain, potentially leading to cognitive impairment in some individuals.
Fatigue and Immune Dysregulation in Long COVID
One of the most commonly reported symptoms in long COVID patients is chronic fatigue, often resembling conditions like myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). The study found that increased levels of suPAR, a biomarker of immune activation, were strongly associated with persistent fatigue. Researcher
s believe that suPAR may contribute to chronic inflammation and mitochondrial dysfunction, which in turn leads to prolonged fatigue and decreased energy levels in affected patients.
Gastrointestinal symptoms such as nausea, abdominal pain, and altered bowel habits were also linked to long COVID. Biomarkers like intestinal fatty acid-binding protein (I-FABP) and zonulin, which are indicators of gut barrier integrity, were found to be elevated in patients with persistent digestive issues. These markers suggest that COVID-19 may disrupt gut health, leading to increased inflammation and gastrointestinal complications in the long term.
Future Implications and Treatment Strategies
The findings from this study have important implications for the management and treatment of long COVID. By identifying key biomarkers associated with prolonged symptoms, researchers hope to develop more targeted and effective treatment approaches. Biomarker profiling could enable doctors to personalize treatment plans based on individual patient needs, leading to better outcomes and faster recovery times.
Furthermore, the integration of biomarker analysis with emerging technologies such as artificial intelligence and machine learning could help predict disease progression and identify patients who are at higher risk for severe complications. This proactive approach may allow healthcare providers to intervene earlier and reduce the burden of long COVID on both patients and healthcare systems.
Conclusion
The study conducted by researchers from "Victor Babes" University of Medicine and Pharmacy represents a major step forward in understanding the long-term effects of COVID-19. By identifying key biomarkers associated with inflammation and tissue damage, the research provides valuable insights into how the virus affects different organ systems and contributes to prolonged symptoms. The findings highlight the importance of continuous monitoring and personalized treatment strategies to improve patient outcomes and address the growing challenges posed by long COVID. As further research unfolds, these biomarkers could become essential tools in guiding future treatment approaches and public health policies aimed at mitigating the long-term impact of COVID-19.
The study findings were published in the peer-reviewed Journal of Clinical Medicine.
https://www.mdpi.com/2077-0383/14/5/1475
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/new-biomarker-offers-insight-into-covid-19-effects-on-bone-health
https://www.thailandmedical.news/news/cardiac-and-inflammatory-biomarkers-linked-to-extubation-failure-in-covid-19-patients
https://www.thailandmedical.news/news/urinary-biomarkers-for-covid-19
https://www.thailandmedical.news/news/hyaluronic-acid-as-a-key-biomarker-for-covid-19-mortality
https://www.thailandmedical.news/articles/coronavirus
https://www.thailandmedical.news/pages/thailand_doctors_listings
Share
Tweet
Share
